P. Ardisson

Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.

I. Ray-Coquard, J. Bergerat, O. Trédan, 2011, Bulletin du cancer.

Gemcitabine and oxaliplatin combination chemotherapy for metastatic well‐differentiated neuroendocrine carcinomas

V. Hervieu, J. Scoazec, J. Chayvialle, 2009, Cancer.

Systemic Bevacizumab for Retinal Angiomatous Proliferation Associated with Retinal Pigment Epithelial Detachment

M. Mauget-Faÿsse, P. Ardisson, N. Abi-Ayad, 2007, European journal of ophthalmology.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.